Increased serum levels of soluble tumor necrosis factor receptor-2 (sTNFR2) in patients with active toxoplasmic retinochoroiditis
AUTOR(ES)
Bessa, Thais Fontes, Cordeiro, Cynthia Azeredo, Gonçalves, Roberto Martins, Young, Lucy H., Campos, Wesley R., Oréfice, Fernando, Teixeira, Antônio L.
FONTE
Braz J Infect Dis
DATA DE PUBLICAÇÃO
2012-12
RESUMO
This study aimed to investigate the serum levels of the cytokine TNF-α and its soluble receptors (sTNFR1 and sTNFR2) in patients with toxoplasmosis retinochoroidits (TR) and controls. 37 patients with TR and 30 subjects with positive serology for toxoplasmosis but without history and signs of uveitis were included in this study. Serum concentrations of TNF-α, sTNFR1, and sTNFR2 were determined by ELISA. Serum concentrations of TNF-α and sTNFR1 were similar in controls (mean ± SD median values; 56.57 ± 141.96 and 504.37 ± 163.87, respectively) and TR patients (mean ± SD values, 121.62 ± 217.56 and 511.15 ± 189.30, respectively). Serum concentrations of sTNFR2 were higher in the uveitis group when compared to the control group (respectively, mean ± SD values, 1734.84 ± 379.32 and 1442.75 ± 309.47; p=0.002). There was no association between the serum levels of the molecules and the time of first symptoms, severity of vitreous haze, size or localization of active lesions, levels of visual acuity, and presence of vasculitis. These results suggest that TR is associated with changes in the circulating levels of inflammatory biomarkers, but they are not correlated with local/ocular signs.
Documentos Relacionados
- Serum levels of neurotrophic factors in active toxoplasmic retinochoroiditis
- Treatment of active toxoplasmic retino-choroiditis.
- Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.
- Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.
- Soluble interleukin-2 receptor levels in serum of patients with demyelinating polyneuropathy associated with monoclonal gammopathy.